<VariationArchive RecordType="classified" VariationID="417316" VariationName="NC_000011.10:g.(?_64803514)_(64810132_?)del" VariationType="Deletion" Accession="VCV000417316" Version="1" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2022-11-05" DateCreated="2017-04-17" MostRecentSubmission="2017-04-17">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="397583" VariationID="417316">
      <GeneList>
        <Gene Symbol="MEN1" FullName="menin 1" GeneID="4221" HGNC_ID="HGNC:7010" Source="submitted" RelationshipType="genes overlapped by variant">
          <Location>
            <CytogeneticLocation>11q13.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="11" Accession="NC_000011.10" start="64803516" stop="64811294" display_start="64803516" display_stop="64811294" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="11" Accession="NC_000011.9" start="64570985" stop="64578765" display_start="64570985" display_stop="64578765" Strand="-" />
          </Location>
          <OMIM>613733</OMIM>
          <Haploinsufficiency last_evaluated="2022-01-12" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=MEN1">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2022-01-12" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=MEN1">No evidence available</Triplosensitivity>
          <Property>gene_acmg_incidental_2013</Property>
          <Property>gene_acmg_incidental_2016</Property>
          <Property>gene_acmg_incidental_2021</Property>
          <Property>gene_acmg_incidental_2022</Property>
        </Gene>
      </GeneList>
      <Name>NC_000011.10:g.(?_64803514)_(64810132_?)del</Name>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>11q13.1</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="11" Accession="NC_000011.9" innerStart="64570986" innerStop="64577604" display_start="64570986" display_stop="64577604" variantLength="6619" />
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="11" Accession="NC_000011.10" innerStart="64803514" innerStop="64810132" display_start="64803514" display_stop="64810132" variantLength="6619" />
      </Location>
      <HGVSlist>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000011.10" sequenceAccession="NC_000011" sequenceVersion="10" change="g.(?_64803514)_(64810132_?)del" Assembly="GRCh38">
            <Expression>NC_000011.10:g.(?_64803514)_(64810132_?)del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000011.9" sequenceAccession="NC_000011" sequenceVersion="9" change="g.(?_64570986)_(64577604_?)del" Assembly="GRCh37">
            <Expression>NC_000011.9:g.(?_64570986)_(64577604_?)del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NC_000011.10:g.(?_64803514)_(64810132_?)del AND Multiple endocrine neoplasia, type 1" Accession="RCV000471021" Version="1">
        <ClassifiedConditionList TraitSetID="5472">
          <ClassifiedCondition DB="MedGen" ID="C0025267">Multiple endocrine neoplasia, type 1</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2016-08-02" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2016-08-02" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2017-04-17" MostRecentSubmission="2017-04-17">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <ConditionList>
          <TraitSet ID="5472" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="12656" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">MEN I</ElementValue>
                <XRef Type="MIM" ID="131100" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">MEA I</ElementValue>
                <XRef Type="MIM" ID="131100" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Endocrine adenomatosis multiple</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">MEN 1</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Wermer syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Multiple endocrine neoplasia, type 1</ElementValue>
                <XRef ID="Multiple+endocrine+neoplasia+type+1/4955" DB="Genetic Alliance" />
                <XRef ID="30664006" DB="SNOMED CT" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">MEN1</ElementValue>
                <XRef Type="MIM" ID="131100" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Multiple endocrine neoplasia type 1 (MEN1) includes varying combinations of more than 20 endocrine and non-endocrine tumors. Endocrine tumors become evident either by overproduction of hormones by the tumor or by growth of the tumor itself. Parathyroid tumors are the most common MEN1-associated endocrinopathy; onset in 90% of individuals is between ages 20 and 25 years with hypercalcemia evident by age 50 years; hypercalcemia causes lethargy, depression, confusion, anorexia, constipation, nausea, vomiting, diuresis, dehydration, hypercalciuria, kidney stones, increased bone resorption/fracture risk, hypertension, and shortened QT interval. Pituitary tumors include prolactinoma (the most common), which manifests as oligomenorrhea/amenorrhea and galactorrhea in females and sexual dysfunction in males. Well-differentiated endocrine tumors of the gastro-entero-pancreatic (GEP) tract can manifest as Zollinger-Ellison syndrome (gastrinoma); hypoglycemia (insulinoma); hyperglycemia, anorexia, glossitis, anemia, diarrhea, venous thrombosis, and skin rash (glucagonoma); and watery diarrhea, hypokalemia, and achlorhydria syndrome (vasoactive intestinal peptide [VIP]-secreting tumor). Carcinoid tumors are non-hormone-secreting and can manifest as a large mass after age 50 years. Adrenocortical tumors can be associated with primary hypercortisolism or hyperaldosteronism. Non-endocrine tumors include facial angiofibromas, collagenomas, lipomas, meningiomas, ependymomas, and leiomyomas.</Attribute>
                <XRef ID="NBK1538" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary cancer syndrome</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="3829" />
                <XRef ID="3829" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301710</ID>
                <ID Source="BookShelf">NBK1538</ID>
              </Citation>
              <Citation Type="Position Statement" Abbrev="ASCO, 2010">
                <ID Source="PubMed">20065170</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="Brandi et al., 2001">
                <ID Source="PubMed">11739416</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NSGC, 2004">
                <ID Source="PubMed">15604628</ID>
              </Citation>
              <Citation Type="Recommendation" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23788249</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="Thakker et al., 2012">
                <ID Source="PubMed">22723327</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG/NSGC, 2015">
                <ID Source="PubMed">25394175</ID>
              </Citation>
              <Citation Type="Recommendation" Abbrev="ACMG, 2015">
                <ID Source="PubMed">25356965</ID>
              </Citation>
              <Citation Type="Recommendation" Abbrev="ACMG, 2016">
                <ID Source="PubMed">27854360</ID>
                <ID Source="DOI">10.1038/gim.2016.190</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Endocrine and Neuroendocrine Neoplasia genetics">
                <ID Source="PubMed">26389271</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Breast and Gynecologic Cancers">
                <ID Source="PubMed">26389210</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <Citation Type="Recommendation" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="Recommendation" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="Position Statement" Abbrev="ASCO, 2015">
                <ID Source="PubMed">26324357</ID>
              </Citation>
              <XRef ID="652" DB="Orphanet" />
              <XRef ID="C0025267" DB="MedGen" />
              <XRef ID="D018761" DB="MeSH" />
              <XRef ID="MONDO:0007540" DB="MONDO" />
              <XRef Type="MIM" ID="131100" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="1076694" SubmissionDate="2017-03-14" DateLastUpdated="2017-04-17" DateCreated="2017-04-17">
        <ClinVarSubmissionID localKey="927491|MedGen:C0025267" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000563777" DateUpdated="2017-04-17" DateCreated="2017-04-17" Type="SCV" Version="2" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2016-08-02">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment Type="public">A gross deletion of the genomic region encompassing the full coding sequence of the MEN1 gene has been identified. The boundaries of this event are unknown as the deletion extends beyond the assayed region for this gene and therefore may encompass additional genes. Loss-of-function variants in MEN1 are known to be pathogenic. Similar deletions encompassing the whole MEN1 coding region have been reported in individuals affected with multiple endocrine neoplasia type 1 (PMID: 11836268, 25527055). For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="MEN1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000011.9:g.(?_64570986)_(64577604_?)del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0025267" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>2017March_Invitae</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="1076694" TraitType="Disease" MappingType="XRef" MappingValue="C0025267" MappingRef="MedGen">
        <MedGen CUI="C0025267" Name="Multiple endocrine neoplasia, type 1" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

